BACKGROUND: Limb muscle dysfunction is prevalent in chronic obstructive pulmonary disease (COPD) and it has important clinical implications, such as reduced exercise tolerance, quality of life, and even survival. Since the previous American Thoracic Society/European Respiratory Society (ATS/ERS) statement on limb muscle dysfunction, important progress has been made on the characterization of this problem and on our understanding of its pathophysiology and clinical implications. PURPOSE: The purpose of this document is to update the 1999 ATS/ERS statement on limb muscle dysfunction in COPD. METHODS: An interdisciplinary committee of experts from the ATS and ERS Pulmonary Rehabilitation and Clinical Problems assemblies determined that the scope of this document should be limited to limb muscles. Committee members conducted focused reviews of the literature on several topics. A librarian also performed a literature search. An ATS methodologist provided advice to the committee, ensuring that the methodological approach was consistent with ATS standards. RESULTS: We identified important advances in our understanding of the extent and nature of the structural alterations in limb muscles in patients with COPD. Since the last update, landmark studies were published on the mechanisms of development of limb muscle dysfunction in COPD and on the treatment of this condition. We now have a better understanding of the clinical implications of limb muscle dysfunction. Although exercise training is the most potent intervention to address this condition, other therapies, such as neuromuscular electrical stimulation, are emerging. Assessment of limb muscle function can identify patients who are at increased risk of poor clinical outcomes, such as exercise intolerance and premature mortality. CONCLUSIONS: Limb muscle dysfunction is a key systemic consequence of COPD. However, there are still important gaps in our knowledge about the mechanisms of development of this problem. Strategies for early detection and specific treatments for this condition are also needed.
BACKGROUND:Limb muscle dysfunction is prevalent in chronic obstructive pulmonary disease (COPD) and it has important clinical implications, such as reduced exercise tolerance, quality of life, and even survival. Since the previous American Thoracic Society/European Respiratory Society (ATS/ERS) statement on limb muscle dysfunction, important progress has been made on the characterization of this problem and on our understanding of its pathophysiology and clinical implications. PURPOSE: The purpose of this document is to update the 1999 ATS/ERS statement on limb muscle dysfunction in COPD. METHODS: An interdisciplinary committee of experts from the ATS and ERS Pulmonary Rehabilitation and Clinical Problems assemblies determined that the scope of this document should be limited to limb muscles. Committee members conducted focused reviews of the literature on several topics. A librarian also performed a literature search. An ATS methodologist provided advice to the committee, ensuring that the methodological approach was consistent with ATS standards. RESULTS: We identified important advances in our understanding of the extent and nature of the structural alterations in limb muscles in patients with COPD. Since the last update, landmark studies were published on the mechanisms of development of limb muscle dysfunction in COPD and on the treatment of this condition. We now have a better understanding of the clinical implications of limb muscle dysfunction. Although exercise training is the most potent intervention to address this condition, other therapies, such as neuromuscular electrical stimulation, are emerging. Assessment of limb muscle function can identify patients who are at increased risk of poor clinical outcomes, such as exercise intolerance and premature mortality. CONCLUSIONS:Limb muscle dysfunction is a key systemic consequence of COPD. However, there are still important gaps in our knowledge about the mechanisms of development of this problem. Strategies for early detection and specific treatments for this condition are also needed.
Authors: F Maltais; P LeBlanc; C Simard; J Jobin; C Bérubé; J Bruneau; L Carrier; R Belleau Journal: Am J Respir Crit Care Med Date: 1996-08 Impact factor: 21.405
Authors: Karine Marquis; Richard Debigaré; Yves Lacasse; Pierre LeBlanc; Jean Jobin; Guy Carrier; François Maltais Journal: Am J Respir Crit Care Med Date: 2002-09-15 Impact factor: 21.405
Authors: Yi-Ping Li; Yuling Chen; Joseph John; Jennifer Moylan; Bingwen Jin; Douglas L Mann; Michael B Reid Journal: FASEB J Date: 2005-03 Impact factor: 5.191
Authors: Leonardo Nogueira; Breanna M Trisko; Frederico L Lima-Rosa; Jason Jackson; Helena Lund-Palau; Masahiro Yamaguchi; Ellen C Breen Journal: J Physiol Date: 2018-06-19 Impact factor: 5.182
Authors: Rafael Mesquita; Sarah Wilke; Dionne E Smid; Daisy Ja Janssen; Frits Me Franssen; Vanessa S Probst; Emiel Fm Wouters; Jean Wm Muris; Fabio Pitta; Martijn A Spruit Journal: Chron Respir Dis Date: 2016-07-08 Impact factor: 2.444
Authors: Mia Moberg; Palchamy Elango; Luigi Ferrucci; Martijn A Spruit; Emiel F Wouters; Erica P A Rutten Journal: Eur J Clin Invest Date: 2015-08-07 Impact factor: 4.686
Authors: F de Blasio; M G Santaniello; F de Blasio; G Mazzarella; A Bianco; L Lionetti; F M E Franssen; L Scalfi Journal: Eur J Clin Nutr Date: 2017-09-13 Impact factor: 4.016